Navigation Links
YM BIOSCIENCES REPORTS DAIICHI-SANKYO ENROLLS FIRST PATIENTS IN PHASE II, FIRST-LINE LUNG CANCER TRIAL WITH NIMOTUZUMAB
Date:6/23/2009

than 3,500 patients reported as having been treated with nimotuzumab worldwide to date, no Grade IV incidents of radiation dermatitis have been described, severe rash has not been observed and reports of the other severe side-effects that are typical of EGFR-targeting molecules have been rare. Nimotuzumab is licensed to YM's majority-owned subsidiary, CIMYM BioSciences Inc., by CIMAB S.A., and was developed at the Center of Molecular Immunology. YM is developing AeroLEF for the treatment of moderate to severe acute pain. The product is differentiated from other approaches using fentanyl because patients can individually control the analgesia required for their differing intensities of pain. AeroLEF met all endpoints in a randomized Phase II trial and is currently being prepared for late-stage development internationally.

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that nimotuzumab will continue to demonstrate a competitive safety profile in ongoing and future clinical trials; that AeroLEF(R) will continue to generate positive efficacy and safety data in future clinical trials; and that YM and its various
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
2. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
3. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
4. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
5. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
6. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
7. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
8. Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer
9. Pressure BioSciences, Inc. Issued First Patent in Canada
10. Neurocrine Biosciences to Present at the BioCentury: Newsmakers in the Biotech Industry Conference
11. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... Communications, a leading provider of strategic communications services to corporations and ... the United States and Europe ... JD, is returning to the firm,s Washington, D.C. ... more than two years of service as Associate Commissioner for the ...
(Date:1/14/2014)... AUSTIN, Texas , Jan. 14, 2014 ... analyze and research medicinal plants and therapeutic derivatives ... industry, health professionals, and researchers about the challenges ... (Logo: http://photos.prnewswire.com/prnh/20100430/DC95601LOGO ) The ...
(Date:1/14/2014)... In recent years, growing suspicion about the pharmaceutical ... and promotion has led to unprecedented levels of public ... about the insidious impact of commercialization of research, has ... the world’s biggest pharmas for illegal marketing activities, allegations ...
(Date:1/14/2014)... , Jan. 14, 2014   Kinaxis ®, provider of ... and sales and operations planning ( S&OP ) service, is ... Summit , which will be held at the Hilton San ... join Kinaxis customer Elisabeth Kaszas , Director of Supply ...
Breaking Biology Technology:Former FDA Associate Commissioner Returns To 3D Communications 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 4World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 5World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 6World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 7World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 8The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2
... BioSciences, Inc. (Nasdaq: SGMO ) announced today that ... on the progress of Sangamo,s ZFP Therapeutic® development programs and ... ET on Friday, October 21, 2011 at the 18th Annual ... in New York City. The presentation will be ...
... Sciences Research Council (BBSRC), among others, have taken the first ... chickens against coccidiosis, the most important parasite of poultry globally. ... proteins from the coccidiosis bug rather than being derived from ... scale than is currently possible so could be used to ...
... 2011 Amgen (NASDAQ: AMGN ) announced today ... to the Company,s Board.  Bradway, 48, is Amgen,s president and ... of Amgen board members to 13. Bradway joined ... as executive vice president and chief financial officer from April ...
Cached Biology Technology:Sangamo BioSciences Announces Presentation at the 18th Annual Newsmakers in the Biotech Industry Conference 2A step towards new vaccines for most important chicken parasite 2A step towards new vaccines for most important chicken parasite 3Amgen Appoints Robert A. Bradway to the Company's Board of Directors 2
(Date:4/17/2014)... of stem cell therapies to cure a variety of ... populations based on cell surface markers. Researchers from the ... is highly expressed in a type of stem cells ... in an article in BioResearch Open Access , ... The article is available free on the ...
(Date:4/17/2014)... Luca Razzari of the nergie Matriaux Tlcommunications Research ... the John R. Evans Leaders Fund of the ... of state-of-the-art biotech and nanophotonics equipment. To this ... Ministre de l,Enseignement suprieur, de la Recherche, de ... new laboratories will help us develop new approaches ...
(Date:4/17/2014)... German . ... also provide us with a continuous stream of information about ... sit still in a car the world glides by ... Seemingly without effort, our brain calculates self-motion from this "optic ... a steady gaze during our own movements. Together with biologists ...
Breaking Biology News(10 mins):New state-of-the-art biotech and nanotech equipment for INRS 2How vision makes sure that little fish do not get carried away 2How vision makes sure that little fish do not get carried away 3How vision makes sure that little fish do not get carried away 4
... ranges of species will have to change dramatically as a ... climate will change more than 100 times faster than the ... published study by Indiana University researchers. The study, which ... future change in suitable habitat will be two to three ...
... of threatened species in the developing world are entirely ... new research by the University of East Anglia (UEA). ... , the study concludes that many species, rather than ... actually be driven to extinction without it. Species such ...
... is also available in Chinese on EurekAlert! ... fossil fuels have increased by 49 per cent in the ... international team, including researchers at the Tyndall Centre for Climate ... in the journal Nature Climate Change , the new ...
Cached Biology News:Study finds climate changes faster than species can adapt 2Study finds climate changes faster than species can adapt 3Farming crucial for threatened species in developing world 2Global carbon emissions reach record 10 billion tons -- threatening 2 degree target 2
... Overhead Drive for individual and parallel agitation ... agitation of DASGIP vessels, featuring range of ... ,Up to 16 overhead drives can be ... Systems fedbatch-pro® and cellferm-pro® for microbiology and ...
The LAS-3000 imaging system combines new CCD camera technology with a simplified user interface to provide significantly improved system sensitivity with a wide range of modularities. This system is...
... your Ion Chromatography requirements, IonQuest will ... The newly developed conductivity detector has ... . In addition to the standard ... with other detectors, such as electrochemical, refractive ...
Capture faint-light images without losing sensitivity or resolution. With its brand new hardware and interface design, the LAS-1000plus turns sample imaging into a simple process....
Biology Products: